Effect of liraglutide on body weight and pain in patients with overweight and knee osteoarthritis: protocol for a randomised, double-blind, placebocontrolled, parallel-group, singlecentre trial
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Effect of liraglutide on body weight and pain in patients with overweight and knee osteoarthritis: protocol for a randomised, double-blind, placebocontrolled, parallel-group, singlecentre trial. / Gudbergsen, Henrik Rindel; Henriksen, Marius; Wæhrens, Eva Ejlersen; Overgaard, Anders; Bliddal, Henning; Christensen, Robin; Boesen, Mikael Ploug; Knop, Filip K Krag; Astrup, Arne; Rasmussen, Marianne Uggen; Bartholdy, Cecilie; Daugaard, Cecilie; Bartels, Else Marie; Ellegaard, Karen; Heitmann, Berit; Kristensen, Lars Erik.
In: B M J Open, Vol. 9, No. 5, e024065, 2019.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Effect of liraglutide on body weight and pain in patients with overweight and knee osteoarthritis: protocol for a randomised, double-blind, placebocontrolled, parallel-group, singlecentre trial
AU - Gudbergsen, Henrik Rindel
AU - Henriksen, Marius
AU - Wæhrens, Eva Ejlersen
AU - Overgaard, Anders
AU - Bliddal, Henning
AU - Christensen, Robin
AU - Boesen, Mikael Ploug
AU - Knop, Filip K Krag
AU - Astrup, Arne
AU - Rasmussen, Marianne Uggen
AU - Bartholdy, Cecilie
AU - Daugaard, Cecilie
AU - Bartels, Else Marie
AU - Ellegaard, Karen
AU - Heitmann, Berit
AU - Kristensen, Lars Erik
N1 - CURIS 2019 NEXS 155
PY - 2019
Y1 - 2019
N2 - Introduction: With an increasing prevalence of citizens of older age and with overweight, the health issues related to knee osteoarthritis (OA) will intensify. Weight loss is considered a primary management strategy in patients with concomitant overweight and knee OA. However, there are no widely available and feasible methods to sustain weight loss in patients with overweight and knee OA. The present protocol describes a randomised controlled trial evaluating the efficacy and safety of the glucagon-like peptide-1 receptor agonist liraglutide in a 3 mg/day dosing in patients with overweight and knee OA.Methods and analysis: 150 volunteer adult patients with overweight or obesity and knee OA will participate in a randomised, double-blind, placebo-controlled, parallel-group and single-centre trial. The participants will partake in a run-in diet intervention phase (week −8 to 0) including a low calorie diet and dietetic counselling. At week 0, patients will be randomised to either liraglutide 3 mg/day or liraglutide placebo 3 mg/day for 52 weeks as an add-on to dietetic guidance on re-introducing regular foods and a focus on continued motivation to engage in a healthy lifestyle. The co-primary outcomes are changes in body weight and the Knee Injury and Osteoarthritis Outcome Score pain subscale from week 0 to week 52.Ethics and dissemination: The trial has been approved by the regional ethics committee in the Capital Region of Denmark, the Danish Medicines Agency and the Danish Data Protection Agency. An external monitoring committee (The Good Clinical Practice Unit at Copenhagen University Hospitals) will oversee the trial. The results will be presented at international scientific meetings and through publications in peer-reviewed journals.Trial registration numbers: 2015-005163-16, NCT02905864, U1111-1171-4970
AB - Introduction: With an increasing prevalence of citizens of older age and with overweight, the health issues related to knee osteoarthritis (OA) will intensify. Weight loss is considered a primary management strategy in patients with concomitant overweight and knee OA. However, there are no widely available and feasible methods to sustain weight loss in patients with overweight and knee OA. The present protocol describes a randomised controlled trial evaluating the efficacy and safety of the glucagon-like peptide-1 receptor agonist liraglutide in a 3 mg/day dosing in patients with overweight and knee OA.Methods and analysis: 150 volunteer adult patients with overweight or obesity and knee OA will participate in a randomised, double-blind, placebo-controlled, parallel-group and single-centre trial. The participants will partake in a run-in diet intervention phase (week −8 to 0) including a low calorie diet and dietetic counselling. At week 0, patients will be randomised to either liraglutide 3 mg/day or liraglutide placebo 3 mg/day for 52 weeks as an add-on to dietetic guidance on re-introducing regular foods and a focus on continued motivation to engage in a healthy lifestyle. The co-primary outcomes are changes in body weight and the Knee Injury and Osteoarthritis Outcome Score pain subscale from week 0 to week 52.Ethics and dissemination: The trial has been approved by the regional ethics committee in the Capital Region of Denmark, the Danish Medicines Agency and the Danish Data Protection Agency. An external monitoring committee (The Good Clinical Practice Unit at Copenhagen University Hospitals) will oversee the trial. The results will be presented at international scientific meetings and through publications in peer-reviewed journals.Trial registration numbers: 2015-005163-16, NCT02905864, U1111-1171-4970
KW - Faculty of Science
KW - Rheumatology
KW - Overweight
KW - Protocol
U2 - 10.1136/bmjopen-2018-024065
DO - 10.1136/bmjopen-2018-024065
M3 - Journal article
C2 - 31061017
VL - 9
JO - BMJ Open
JF - BMJ Open
SN - 2044-6055
IS - 5
M1 - e024065
ER -
ID: 217551349